

## Industry: Medical Devices

- Cardiology: Advanced analysis of whole-heart function
- Key Applications: Congenital Heart Disease, Oncology, Hypertension, High Risk Pregnancy, COVID-19

## Management

Dr. Alvira Macanovic  
President and CEO

Mr. Victor Hugo  
CFO

Mr. Desmond Hirson  
Technology Advisor

## Board of Directors & Advisory Team

Dr. George Adams, Chairman  
Mr. Robert Hodgkinson, Director  
Mr. Hugh MacNaught, Director  
Ms. Fiona Fitzgerald, Director  
Mr. Randy AuCoin, Director  
Mr. Samuel Schwartz, Advisor

## Auditors

MNP LLP

## Legal Counsel

Boyle & Co LLP

## Dr. Gregory Skinner

Consultant Paediatric Cardiologist at the East Midlands Congenital Heart Centre in Leicester, UK Clinical Lead for the Department of Paediatric Cardiology and Deputy Head of Service for the East Midlands Congenital Heart Centre.

*"I have been using the Ventripoint system since 2014, and it has proved to be a valuable tool for measuring right ventricular size and function in patients with congenital heart disease. It is an excellent adjunct to MRI, allowing accurate and reproducible measurements by using echocardiography."*

## Intellectual Property

- Exclusive worldwide license to all technology
- PCT patent applications covering proprietary sensor technology and dynamic measurements

## Key Milestones & Capabilities


- Received FDA Clearance, Health Canada License and CE Mark
- Over 60 publications using the system with installations and use cases by Key Opinion Leaders globally
- CPT Reimbursement Codes 76377 and +93319 (U.S. Market)

## Executive Summary:

- Ventripoint Diagnostics is a publicly-traded company (TSXV:VPT, OTC:VPTDF), which is focused on the development and commercialization of diagnostic tools to monitor patients with heart disease. Its flagship product, the VMS+3.0, is the first and only cost-effective and accurate diagnostic tool to measure the volume and function of all 4 chambers of the heart and is uniquely able to evaluate the heart's right ventricle, which is particularly difficult to image and analyze with ultrasound.
- Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.

## Market Opportunity/Unmet Need:

- In the case of cardiac imaging, ultrasound provides basic but limited and inconsistent data regarding the volumes of the four chambers of the heart, the amount of blood being pumped through those chambers, and the condition of the valves.
- While echocardiography guidelines call for volumetric assessments on every patient, cardiologists have traditionally only referred their most difficult patients for a cardiac MRI (cMRI) which is the gold standard for the calculation of volumes and ejection fractions. cMRI cannot be widely used given its limited accessibility in most communities, more significant cost, long duration (~1+ hr), requirement for injection of contrast media and frequent need for sedation of the patient. All of this is traumatic to patients, especially children.
- With the Ventripoint system, most patients can be examined with inexpensive and readily available 2D ultrasound equipment, producing MRI-quality data for volumes and cardiac chamber shapes in 10-15 minutes at minimal cost.
- The total addressable market for the VMS+ is \$1.7B which is segmented into three key market segments: Congenital, Oncology, and High-risk pregnancy.



Shares Issued and Outstanding	156.8M
Options @ \$.25	9.7M
Warrants @ \$.68	15.6M
Debt	None
Fully Diluted	182M
Market Cap	\$24.4M (CAD)
Cash (March 31, 2023)	\$4.3M